Neurocrine Biosciences Inc (NBIX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.73 is considered Undervalued compared with the five-year average of 21.37. The fair price of Neurocrine Biosciences Inc (NBIX) is between 147.81 to 207.89 according to relative valuation method. Compared to the current price of 132.38 USD , Neurocrine Biosciences Inc By Undervalued By 10.44%.

Relative Value

Fair Zone

147.81-207.89

Current Price：132.38

10.44%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Neurocrine Biosciences Inc (NBIX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Neurocrine Biosciences Inc (NBIX) has a current Price-to-Book (P/B) ratio of 4.67. Compared to its 3-year average P/B ratio of 5.28, the current P/B ratio is approximately -11.56% higher. Relative to its 5-year average P/B ratio of 5.89, the current P/B ratio is about -20.75% higher. Neurocrine Biosciences Inc (NBIX) has a Forward Free Cash Flow (FCF) yield of approximately 4.23%. Compared to its 3-year average FCF yield of 3.61%, the current FCF yield is approximately 17.30% lower. Relative to its 5-year average FCF yield of 3.12%, the current FCF yield is about 35.73% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NBIX competitors is 40.47, providing a benchmark for relative valuation. Neurocrine Biosciences Inc Corp (NBIX.O) exhibits a P/S ratio of 4.25, which is -89.5% above the industry average. Given its robust revenue growth of 28.33%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NBIX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NBIX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NBIX currently overvalued or undervalued?

Neurocrine Biosciences Inc (NBIX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.73 is considered Undervalued compared with the five-year average of 21.37. The fair price of Neurocrine Biosciences Inc (NBIX) is between 147.81 to 207.89 according to relative valuation method. Compared to the current price of 132.38 USD, Neurocrine Biosciences Inc is Undervalued By 10.44%.

What is Neurocrine Biosciences Inc (NBIX) fair value?

NBIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Neurocrine Biosciences Inc (NBIX) is between 147.81 to 207.89 according to relative valuation method.

How does NBIX's valuation metrics compare to the industry average?

The average P/S ratio for NBIX's competitors is 40.47, providing a benchmark for relative valuation. Neurocrine Biosciences Inc Corp (NBIX) exhibits a P/S ratio of 4.25, which is -89.50% above the industry average. Given its robust revenue growth of 28.33%, this premium appears sustainable.

What is the current P/B ratio for Neurocrine Biosciences Inc (NBIX) as of Mar 02 2026?

As of Mar 02 2026, Neurocrine Biosciences Inc (NBIX) has a P/B ratio of 4.67. This indicates that the market values NBIX at 4.67 times its book value.

What is the current FCF Yield for Neurocrine Biosciences Inc (NBIX) as of Mar 02 2026?

As of Mar 02 2026, Neurocrine Biosciences Inc (NBIX) has a FCF Yield of 4.23%. This means that for every dollar of Neurocrine Biosciences Inc's market capitalization, the company generates 4.23 cents in free cash flow.

What is the current Forward P/E ratio for Neurocrine Biosciences Inc (NBIX) as of Mar 02 2026?

As of Mar 02 2026, Neurocrine Biosciences Inc (NBIX) has a Forward P/E ratio of 15.73. This means the market is willing to pay $15.73 for every dollar of Neurocrine Biosciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Neurocrine Biosciences Inc (NBIX) as of Mar 02 2026?

As of Mar 02 2026, Neurocrine Biosciences Inc (NBIX) has a Forward P/S ratio of 4.25. This means the market is valuing NBIX at $4.25 for every dollar of expected revenue over the next 12 months.

NBIX Valuation